Alnylam Drops Label-Expansion Effort For Onpattro After FDA Complete Response

 
• By Joseph Haas

Giving up on adding a cardiomyopathy indication to Onpattro’s label, Alnylam now will focus on adding that disease to Amvuttra’s label. Onpattro got a thumbs-up from an FDA advisory panel in September.

Change of plan
Alnylam has revised its plans in cardiomyopathy following an FDA rejection • Source: Shutterstock

More from Strategy

More from Business